Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720896 | 0.89 | PIK3CD (0.38) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL12208456 | 0.83 | PIK3CD (0.38) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15549868 | 0.81 | PIK3CD (0.36) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15548788 | 0.76 | TSHR (0.39) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL84388 | 0.75 | GSK3A (0.35) | PTGS1GSK3AGSK3BCRBNBRD4 | |
| SCHEMBL9720746 | 0.73 | PTGS1 (0.56) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL9720830 | 0.73 | PTGS1 (0.56) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL9720744 | 0.73 | PTGS1 (0.56) | PIK3CDMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL1101974 | 0.71 | MC4R (0.53) | MEN1LMNAKMT2AGSK3AGSK3B | |
| SCHEMBL15062099 | 0.71 | GSK3A (0.32) | GSK3AGSK3BCRBNBRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5421897-A | Applying liquid composition to surface contaminated with lead, solidifying into matrix which sequesters lead, removing matrix | GRAWE JOHN (US) | 1995-06-06 | — | — | US | claimed |
| WO-1992000740-A2 | BIS-DIOXOPIPERAZINES AND THEIR USE AS PROTECTION AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-01-23 | — | — | WO | claimed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-06-10 | — | — | US | disclosed |
| EP-2035003-A1 | A METHOD OF REDUCING AMYLOID-BETA PEPTIDE LEVELS USING A BISDIOXOPIPERAZINE | The Govt Of The USA, As Represented By The Secretary, Department Of Health And Human Services (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146178-A1 | A METHOD OF REDUCING AMYLOID-BETA PEPTIDE LEVELS USING A BISDIOXOPIPERAZINE | THE GOVT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, (US) | 2007-12-21 | — | — | WO | disclosed |
| US-5421897-A | Applying liquid composition to surface contaminated with lead, solidifying into matrix which sequesters lead, removing matrix | GRAWE JOHN (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1992000740-A2 | BIS-DIOXOPIPERAZINES AND THEIR USE AS PROTECTION AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | IAPP, APP, BACE1 | PIK3CD 4772/4885MEN1 1316/4885LMNA 2044/4885 |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | PIK3CD 2971/4885MEN1 362/4885LMNA 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.